Ignacio Durán

Suggest Changes

Writes About:

Learn More
Background There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene(More)